Canadian Patients Now Have Access to Long-Term, Continuous Monitoring of
MISSISSAUGA, ON, March 31 /CNW/ - Today Medtronic of Canada Ltd.
announced the Canadian introduction of the Reveal(R) XT Insertable Cardiac
Monitor (ICM), which offers long-term and continuous monitoring of Atrial
Fibrillation (AF). Long-term, continuous monitoring means that a clinician no
longer needs to rely only on incomplete data to evaluate how AF may be
progressing or if treatment is effective. The first implants of the Reveal XT
monitor in North America recently took place at London Health Sciences
Centre's University Hospital, London, Ontario by Dr. Lorne Gula and Dr. Allan
AF is the most common cardiac arrhythmia, yet treatment is difficult as
episodes often have no symptoms and therefore go unnoticed by patients(1).
However, the risks are well known - AF can lead to a two to seven times higher
risk of stroke(2), an increased risk of heart failure(3) if rapid heart rates
persist undetected for long periods of time.
The Reveal XT Insertable Cardiac Monitor monitors patients 24 hours a
day, every day for up to three years. There are a variety of ways to treat AF,
but previously physicians had no means of gathering detailed data, over an
extended period, on the progression of AF and the effect of treatment. Reveal
XT gives new insight into patients' heart rhythms, which may help physicians
to make informed decisions about the patient's need for medication,
cardioversion or other rate or rhythm control therapy.
As the Reveal XT monitor is inserted just under the skin, the patient
experiences no restrictions in daily activities. Patients continue to lead
their normal life and, therefore, heart activity recorded shows real-life,
The device weighs just 15 grams and is approximately the size of a memory
stick; unlike a pacemaker or implantable cardioverter-defibrillator, there are
no leads (tiny wires) that extend from the device into the heart's chamber(s).
Electrocardiograms (ECGs) are recorded automatically and/or using a "Patient
Assistant." To use the "Assistant," a patient places a hand-held activator
over the device, and presses a button; a physician later analyzes the stored
In addition to the Reveal XT ICM, the Reveal(R) DX ICM also is now
commercially available in Canada. The Reveal DX device continuously monitors
the heart's electrical activity in order to help physicians diagnose whether
or not symptoms such as fainting, dizziness and unexplained seizure-like
episodes have a cardiac cause. The new Reveal devices provide significant
improvements and advances over the cardiac monitoring technology Medtronic
pioneered with the Reveal(R) Insertable Loop Recorder, which was jointly
developed by Medtronic and George Klein, M.D., of London Health Sciences
Centre's University Hospital, London, Ontario.
(1) T. Fetsch, EHJ. 2004;1385-1394
(2) ACC/AHA/ESC Guidelines for the Management of Patients with Atrial
(3) A. Krahn et al. Am J Med. 1995; 98:476-484
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the
global leader in medical technology - alleviating pain, restoring health, and
extending life for millions of people around the world.
About Medtronic of Canada Ltd.
Medtronic of Canada sells, services and distributes Medtronic products in
Canada: medical devices used in cardiovascular medicine, diabetes, spinal and
neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs
over 400 Canadians, it is headquartered in Mississauga, Ontario since 1972 and
has regional offices in Vancouver and Montreal.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's Annual Report on Form 10-K for the year
ended April 27, 2007. Actual results may differ materially from anticipated
For further information:
For further information: Lynda Pike, Public Relations, (905) 816-5226